Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
May 6, 2026
Reporting period
Not applicable
Filed with the SEC
May 8, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001682852-26-000097
Filed / recorded
May 8, 2026, 9:07 PM UTC
Added to OQRO
Oct 2, 2026, 12:28 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
Moderna, Inc.
Issuer CIK
1682852
Ticker
MRNA
Reporting person
David M. Rubenstein
Relationship
Director
Security
Stock Option (Right to Buy)
Table
Derivative (Table II)
Transaction date
May 6, 2026
Transaction code
A
Shares / units
9,681
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
9,681
Ownership form
Direct
Amendment
No
Footnotes from the filing
This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.